Condition
    Moderate Evidence
    Effectiveness 3/5

    Vitamin D for Vertigo Disorder

    Correcting vitamin D deficiency measurably reduced BPPV recurrence in randomised testing — one of the few supplement findings in vestibular medicine with real support.

    Overview

    The vertigo in question here is benign paroxysmal positional vertigo — brief spinning triggered by head movement, caused by displaced calcium carbonate crystals in the inner ear. That the crystals are calcium-based is what makes vitamin D interesting: several observational studies find lower 25-hydroxyvitamin D in people with BPPV, and a 2024 meta-analysis in BMJ Open confirmed an association with both incidence and recurrence. The practical finding comes from a 2020 Neurology randomised trial, which gave vitamin D and calcium to BPPV patients with low vitamin D after successful repositioning and found a meaningfully lower recurrence rate over a year. Subsequent systematic reviews support this in deficient patients while noting the evidence base is small. Vitamin D does not treat an attack — canalith repositioning does that — it reduces the odds of the next one in people who are deficient.

    Verdict

    Likely effective

    A randomised trial and supporting meta-analyses show vitamin D with calcium reduces BPPV recurrence in patients with low baseline vitamin D. It does not resolve an acute attack, and evidence in replete patients is absent.

    How It Works

    Otoconia are calcium carbonate crystals bound to a protein matrix on the utricular macula. Their formation, maintenance and resorption depend on tightly regulated calcium handling in the inner ear endolymph, and vitamin D receptors and calcium transport proteins are expressed in the vestibular epithelium. The prevailing hypothesis is that vitamin D deficiency disturbs local calcium homeostasis, leaving otoconia demineralised and more prone to detaching and drifting into a semicircular canal. The same logic explains the observed epidemiology. BPPV is commoner in older adults, in women after menopause and in people with osteoporosis — all groups with disturbed calcium and vitamin D metabolism and reduced bone mineral density. Correcting deficiency is thought to support otoconial integrity and reduce the rate at which crystals dislodge, which fits the recurrence-focused rather than attack-focused benefit seen in the trial data.

    Pathways involved

    Otoconial calcium carbonate metabolism
    Endolymph calcium homeostasis
    Vestibular vitamin D receptor expression
    Bone mineral density and osteoporosis overlap
    Oestrogen-related calcium handling

    Dosing & Protocol

    The Neurology recurrence trial gave 400 IU of vitamin D twice daily — 800 IU total — together with 500 mg of calcium carbonate twice daily, to patients whose serum 25-hydroxyvitamin D was below 20 ng/mL, following successful canalith repositioning. That combination, not vitamin D alone, is what was tested, and the benefit appeared over roughly one year of follow-up. In practice a 1,000 to 2,000 IU daily dose is a reasonable general target where testing is unavailable, taken with a fat-containing meal. What the evidence does not support is supplementing vertigo patients whose vitamin D is already adequate, since the trial and reviews restricted benefit to deficient participants. Recurrence is measured over months, so this is a twelve-month judgement, not a twelve-day one.
    ScenarioDoseCo-therapyNotes
    Trial protocol (recurrence prevention)400 IU twice daily (800 IU/day)500 mg calcium carbonate twice dailyOnly in patients with 25(OH)D below 20 ng/mL
    Practical maintenance1,000-2,000 IU/dayDietary calcium or supplementWith a fat-containing meal
    Documented deficiencyLoading then 800-2,000 IU/dayPer clinicianRecheck level at 3 months
    Already repleteNo supplementation indicated-Benefit was confined to deficient patients
    Assessment window12 months-Endpoint is recurrence rate, not symptom relief
    Upper limit4,000 IU/day-Above this only with monitoring
    1. 1

      Get the diagnosis confirmed· Before starting

      BPPV is diagnosed on positional testing such as Dix-Hallpike. Vertigo has many other causes, several of them urgent.

    2. 2

      Have the repositioning manoeuvre done first· At diagnosis

      Epley or an equivalent canalith repositioning procedure is the treatment for the attack. Vitamin D does nothing for crystals already in the canal.

    3. 3

      Measure 25-hydroxyvitamin D· After repositioning

      The trial enrolled only patients below 20 ng/mL. If yours is normal, supplementation is not supported by the evidence.

    4. 4

      Start vitamin D with calcium if deficient· Months 1-12

      800 IU vitamin D and 1,000 mg calcium carbonate daily in divided doses, as used in the trial.

    5. 5

      Track recurrences· Month 12

      Note the date of each episode. The measurable outcome is fewer recurrences per year, which needs a year to assess.

    Evidence

    The 2020 Neurology randomised trial is the anchor. Patients with BPPV and low serum vitamin D were randomised after successful repositioning to vitamin D plus calcium or to observation, and the supplemented group had a significantly lower annual recurrence rate. It is an open-label intervention trial, which is a limitation, but it is a proper randomised comparison with a clinically meaningful endpoint. The 2021 meta-analysis in Science Progress pooled the available supplementation studies and found reduced BPPV recurrence, and the 2022 systematic review in Otology and Neurotology reached a similar conclusion while emphasising the small number of trials and their heterogeneity. The 2024 BMJ Open meta-analysis addressed the upstream question and confirmed an association between vitamin D deficiency and both BPPV incidence and recurrence. The consistent thread across all four is that the benefit belongs to deficient patients.
    Best available evidence
    One randomised trial, two meta-analyses, one systematic review
    Typical effect
    Reduced annual BPPV recurrence rate in vitamin D deficient patients
    Studied dose
    800 IU/day vitamin D with 1,000 mg/day calcium carbonate
    Who benefits
    Patients with 25(OH)D below 20 ng/mL and recurrent BPPV
    What it does not do
    Resolve an acute attack; repositioning manoeuvres do that
    Certainty of evidence
    Moderate in deficient patients; no evidence of benefit in replete patients

    The randomised trial of vitamin D and calcium for BPPV recurrence prevention, two meta-analyses of supplementation and of the deficiency association, and a systematic review of vitamin D supplementation in BPPV.

    Effect of vitamin D supplementation on benign paroxysmal positional vertigo recurrence: A meta-analysis

    Score: 7/10
    2021
    meta_analysis

    Vitamin D supplementation significantly reduced recurrence of benign paroxysmal positional vertigo in pooled analysis.

    View source

    Prevention of benign paroxysmal positional vertigo with vitamin D supplementation: A randomized trial

    Score: 8/10
    2020
    rct
    n=957

    Jeong SH, Kim JS, Kim HJ

    Supplementation with vitamin D and calcium reduced the annual recurrence of benign paroxysmal positional vertigo in patients with low vitamin D.

    View source

    Vitamin D Supplementation for Benign Paroxysmal Positional Vertigo: A Systematic Review

    Score: 6/10
    2022
    systematic_review

    Most studies reported fewer BPPV recurrences with vitamin D supplementation.

    View source

    Association between vitamin D deficiency and benign paroxysmal positional vertigo (BPPV) incidence and recurrence: a systematic review and meta-analysis

    Score: 7/10
    2024
    meta_analysis

    Vitamin D deficiency was associated with both incidence and recurrence of benign paroxysmal positional vertigo.

    View source

    Safety

    Vitamin D at 800 to 2,000 IU daily is well tolerated, with an adult upper intake level of 4,000 IU per day. Toxicity requires sustained intakes well above that and presents as hypercalcaemia — nausea, thirst, frequent urination, confusion, and with prolonged exposure kidney stones and renal impairment. Sarcoidosis, tuberculosis and other granulomatous conditions convert vitamin D without normal feedback control and need specialist supervision. The calcium half of the protocol carries its own considerations. Calcium carbonate commonly causes constipation and bloating, needs stomach acid for absorption so should be taken with food, and supplemental calcium raises kidney stone risk in susceptible people. There is also longstanding debate about calcium supplements and cardiovascular risk, which is a reason to prefer dietary calcium where intake is already adequate. Most importantly: vertigo with hearing loss, double vision, weakness, slurred speech, severe headache or unsteadiness that persists between episodes is not BPPV and needs urgent assessment.

    Vertigo that is not BPPV

    Sudden hearing loss, double vision, facial weakness, slurred speech, severe headache, or continuous imbalance between episodes point away from BPPV and toward causes that need immediate medical assessment.

    Interactions & Conflicts

    Interacts withSeverityMechanismAction
    Thiazide diuretics
    moderate
    		Reduced urinary calcium excretion combined with vitamin D and calcium raises hypercalcaemia riskMonitor serum calcium
    Sarcoidosis and granulomatous disease
    high
    		Unregulated activation of vitamin D causes hypercalcaemiaOnly under specialist supervision
    Levothyroxine
    moderate
    		Calcium carbonate reduces levothyroxine absorptionSeparate by at least 4 hours
    Tetracycline and quinolone antibiotics
    moderate
    		Calcium chelates these antibiotics and reduces absorptionSeparate by 2-4 hours
    Digoxin
    moderate
    		Raised calcium increases digoxin toxicity riskMonitor calcium and digoxin levels
    History of calcium kidney stones
    moderate
    		Supplemental calcium increases stone riskPrefer dietary calcium; discuss with clinician
    Chronic kidney disease
    moderate
    		Altered calcium-phosphate handling and vitamin D activationDosing directed by nephrology

    References

    1. Jeong SH et al. Prevention of benign paroxysmal positional vertigo with vitamin D supplementation: a randomized trial. Neurology. 2020
    2. Effect of vitamin D supplementation on benign paroxysmal positional vertigo recurrence: a meta-analysis. Sci Prog. 2021
    3. Vitamin D supplementation for benign paroxysmal positional vertigo: a systematic review. Otol Neurotol. 2022

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.